Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Late-Stage Pipeline

33%

2 trials in Phase 3/4

Results Transparency

0 of 0 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 2

3(50.0%)

Phase 3

2(33.3%)

N/A

1(16.7%)

6Total

Phase 2(3)

Phase 3(2)

N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials

NCT07486687Phase 3Not Yet Recruiting

Pembrolizumab Adjuvant in Patients With Early-stage Triple Negative Breast Cancer With Residual Disease After Neoadjuvant Pembrolizumab Plus Chemotherapy

Role: collaborator

NCT07237256Phase 3Recruiting

Chemotherapy De-escalation in HR +, HER2-, Intermediate-risk Early Breast Cancer Treated With Adjuvant Ribociclib

Role: collaborator

NCT04489173Phase 2Active Not Recruiting

TAS102 in Patients With ER-positive, HER2-negative Advanced Breast Cancer

Role: collaborator

NCT03820063Phase 2Active Not Recruiting

Image-guided De-escalation of Neo-adjuvant Chemotherapy in HER2-positive Breast Cancer: the TRAIN-3 Study

Role: collaborator

NCT05392608Phase 2Active Not Recruiting

SEQUence of Endocrine Therapy in Advanced Luminal Breast Cancer (SEQUEL-Breast)

Role: collaborator

NCT04125277Not ApplicableActive Not Recruiting

The SONImage Study

Role: collaborator

All 6 trials loaded